Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Genomic Profiling of Biliary Tract Cancer Cell Lines Reveals Molecular Subtypes and Actionable Drug Targets.

Lau DK, Mouradov D, Wasenang W, Luk IY, Scott CM, Williams DS, Yeung YH, Limpaiboon T, Iatropoulos GF, Jenkins LJ, Reehorst CM, Chionh F, Nikfarjam M, Croagh D, Dhillon AS, Weickhardt AJ, Muramatsu T, Saito Y, Tebbutt NC, Sieber OM, Mariadason JM.

iScience. 2019 Oct 31;21:624-637. doi: 10.1016/j.isci.2019.10.044. [Epub ahead of print]

2.

Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer.

Williams DS, Mouradov D, Browne C, Palmieri M, Elliott MJ, Nightingale R, Fang CG, Li R, Mariadason JM, Faragher I, Jones IT, Churilov L, Tebbutt NC, Gibbs P, Sieber OM.

Mod Pathol. 2019 Aug 30. doi: 10.1038/s41379-019-0353-2. [Epub ahead of print]

PMID:
31471586
3.

Loss of Bcl-G, a Bcl-2 family member, augments the development of inflammation-associated colorectal cancer.

Nguyen PM, Dagley LF, Preaudet A, Lam N, Giam M, Fung KY, Aizel K, van Duijneveldt G, Tan CW, Hirokawa Y, Yip HYK, Love CG, Poh AR, Cruz A, Burstroem C, Feltham R, Abdirahman SM, Meiselbach K, Low RRJ, Palmieri M, Ernst M, Webb AI, Burgess T, Sieber OM, Bouillet P, Putoczki TL.

Cell Death Differ. 2019 Jul 11. doi: 10.1038/s41418-019-0383-9. [Epub ahead of print]

PMID:
31296963
4.

Evaluation of the transferability of survival calculators for stage II/III colon cancer across healthcare systems.

Jorissen RN, Croxford M, Jones IT, Ward RL, Hawkins NJ, Gibbs P, Sieber OM.

Int J Cancer. 2019 Jul 1;145(1):132-142. doi: 10.1002/ijc.32100. Epub 2019 Jan 20.

PMID:
30620048
5.

Immunoscore-has it scored for colon cancer precision medicine?

Jorissen RN, Sakthianandeswaren A, Sieber OM.

Ann Transl Med. 2018 Nov;6(Suppl 1):S23. doi: 10.21037/atm.2018.09.29. No abstract available.

6.

Ponatinib Inhibits Multiple Signaling Pathways Involved in STAT3 Signaling and Attenuates Colorectal Tumor Growth.

Tan FH, Putoczki TL, Lou J, Hinde E, Hollande F, Giraud J, Stylli SS, Paradiso L, Zhu HJ, Sieber OM, Luwor RB.

Cancers (Basel). 2018 Dec 19;10(12). pii: E526. doi: 10.3390/cancers10120526.

7.

MACROD2 deletions cause impaired PARP1 activity and chromosome instability in colorectal cancer.

Sakthianandeswaren A, Parsons MJ, Mouradov D, Sieber OM.

Oncotarget. 2018 Sep 4;9(69):33056-33058. doi: 10.18632/oncotarget.25887. eCollection 2018 Sep 4. No abstract available.

8.

MACROD2 Haploinsufficiency Impairs Catalytic Activity of PARP1 and Promotes Chromosome Instability and Growth of Intestinal Tumors.

Sakthianandeswaren A, Parsons MJ, Mouradov D, MacKinnon RN, Catimel B, Liu S, Palmieri M, Love C, Jorissen RN, Li S, Whitehead L, Putoczki TL, Preaudet A, Tsui C, Nowell CJ, Ward RL, Hawkins NJ, Desai J, Gibbs P, Ernst M, Street I, Buchert M, Sieber OM.

Cancer Discov. 2018 Aug;8(8):988-1005. doi: 10.1158/2159-8290.CD-17-0909. Epub 2018 Jun 7.

9.

Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ-Dependent Manner.

Eissmann MF, Dijkstra C, Wouters MA, Baloyan D, Mouradov D, Nguyen PM, Davalos-Salas M, Putoczki TL, Sieber OM, Mariadason JM, Ernst M, Masson F.

Cancer Immunol Res. 2018 Apr;6(4):409-421. doi: 10.1158/2326-6066.CIR-17-0218. Epub 2018 Feb 20.

10.

Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes.

Williams DS, Mouradov D, Jorissen RN, Newman MR, Amini E, Nickless DK, Teague JA, Fang CG, Palmieri M, Parsons MJ, Sakthianandeswaren A, Li S, Ward RL, Hawkins NJ, Faragher I, Jones IT, Gibbs P, Sieber OM.

Gut. 2018 Jan 30. pii: gutjnl-2017-315664. doi: 10.1136/gutjnl-2017-315664. [Epub ahead of print]

PMID:
29382774
11.

DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis.

Tögel L, Nightingale R, Wu R, Chüeh AC, Al-Obaidi S, Luk I, Dávalos-Salas M, Chionh F, Murone C, Buchanan DD, Chatterton Z, Sieber OM, Arango D, Tebbutt NC, Williams D, Dhillon AS, Mariadason JM.

Sci Rep. 2018 Jan 29;8(1):1767. doi: 10.1038/s41598-018-20176-9.

12.

Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug Sensitivity.

Wang J, Mouradov D, Wang X, Jorissen RN, Chambers MC, Zimmerman LJ, Vasaikar S, Love CG, Li S, Lowes K, Leuchowius KJ, Jousset H, Weinstock J, Yau C, Mariadason J, Shi Z, Ban Y, Chen X, Coffey RJC, Slebos RJC, Burgess AW, Liebler DC, Zhang B, Sieber OM.

Gastroenterology. 2017 Oct;153(4):1082-1095. doi: 10.1053/j.gastro.2017.06.008. Epub 2017 Jun 16.

13.

Analysis of Mammalian Cell Proliferation and Macromolecule Synthesis Using Deuterated Water and Gas Chromatography-Mass Spectrometry.

Foletta VC, Palmieri M, Kloehn J, Mason S, Previs SF, McConville MJ, Sieber OM, Bruce CR, Kowalski GM.

Metabolites. 2016 Oct 13;6(4). pii: E34.

14.

Long noncoding RNA LINP1: scaffolding non-homologous end joining.

Sakthianandeswaren A, Liu S, Sieber OM.

Cell Death Discov. 2016 Jul 18;2:16059. doi: 10.1038/cddiscovery.2016.59. eCollection 2016. No abstract available.

15.

BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression.

Barras D, Missiaglia E, Wirapati P, Sieber OM, Jorissen RN, Love C, Molloy PL, Jones IT, McLaughlin S, Gibbs P, Guinney J, Simon IM, Roth AD, Bosman FT, Tejpar S, Delorenzi M.

Clin Cancer Res. 2017 Jan 1;23(1):104-115. doi: 10.1158/1078-0432.CCR-16-0140. Epub 2016 Jun 27.

16.

Relative telomere lengths in tumor and normal mucosa are related to disease progression and chromosome instability profiles in colorectal cancer.

Suraweera N, Mouradov D, Li S, Jorissen RN, Hampson D, Ghosh A, Sengupta N, Thaha M, Ahmed S, Kirwan M, Aleva F, Propper D, Feakins RM, Vulliamy T, Elwood NJ, Tian P, Ward RL, Hawkins NJ, Xu ZZ, Molloy PL, Jones IT, Croxford M, Gibbs P, Silver A, Sieber OM.

Oncotarget. 2016 Jun 14;7(24):36474-36488. doi: 10.18632/oncotarget.9015.

17.

Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.

Tögel L, Nightingale R, Chueh AC, Jayachandran A, Tran H, Phesse T, Wu R, Sieber OM, Arango D, Dhillon AS, Dawson MA, Diez-Dacal B, Gahman TC, Filippakopoulos P, Shiau AK, Mariadason JM.

Mol Cancer Ther. 2016 Jun;15(6):1217-26. doi: 10.1158/1535-7163.MCT-15-0724. Epub 2016 Mar 16.

18.

Differential RNA-seq analysis comparing APC-defective and APC-restored SW480 colorectal cancer cells.

King LE, Love CG, Sieber OM, Faux MC, Burgess AW.

Genom Data. 2016 Feb 3;7:293-6. doi: 10.1016/j.gdata.2016.02.001. eCollection 2016 Mar.

19.

Colorectal cancer atlas: An integrative resource for genomic and proteomic annotations from colorectal cancer cell lines and tissues.

Chisanga D, Keerthikumar S, Pathan M, Ariyaratne D, Kalra H, Boukouris S, Mathew NA, Al Saffar H, Gangoda L, Ang CS, Sieber OM, Mariadason JM, Dasgupta R, Chilamkurti N, Mathivanan S.

Nucleic Acids Res. 2016 Jan 4;44(D1):D969-74. doi: 10.1093/nar/gkv1097. Epub 2015 Oct 22.

20.

Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancer.

Jorissen RN, Christie M, Mouradov D, Sakthianandeswaren A, Li S, Love C, Xu ZZ, Molloy PL, Jones IT, McLaughlin S, Ward RL, Hawkins NJ, Ruszkiewicz AR, Moore J, Burgess AW, Busam D, Zhao Q, Strausberg RL, Lipton L, Desai J, Gibbs P, Sieber OM.

Br J Cancer. 2015 Sep 15;113(6):979-88. doi: 10.1038/bjc.2015.296. Epub 2015 Aug 25.

21.

The intestinal epithelial cell differentiation marker intestinal alkaline phosphatase (ALPi) is selectively induced by histone deacetylase inhibitors (HDACi) in colon cancer cells in a Kruppel-like factor 5 (KLF5)-dependent manner.

Shin J, Carr A, Corner GA, Tögel L, Dávalos-Salas M, Tran H, Chueh AC, Al-Obaidi S, Chionh F, Ahmed N, Buchanan DD, Young JP, Malo MS, Hodin RA, Arango D, Sieber OM, Augenlicht LH, Dhillon AS, Weber TK, Mariadason JM.

J Biol Chem. 2015 Jun 19;290(25):15392. doi: 10.1074/jbc.A114.557546. No abstract available.

22.

FunRich: An open access standalone functional enrichment and interaction network analysis tool.

Pathan M, Keerthikumar S, Ang CS, Gangoda L, Quek CY, Williamson NA, Mouradov D, Sieber OM, Simpson RJ, Salim A, Bacic A, Hill AF, Stroud DA, Ryan MT, Agbinya JI, Mariadason JM, Burgess AW, Mathivanan S.

Proteomics. 2015 Aug;15(15):2597-601. doi: 10.1002/pmic.201400515. Epub 2015 Jun 17.

PMID:
25921073
23.

Single nucleotide polymorphism array profiling identifies distinct chromosomal aberration patterns across colorectal adenomas and carcinomas.

Zarzour P, Boelen L, Luciani F, Beck D, Sakthianandeswaren A, Mouradov D, Sieber OM, Hawkins NJ, Hesson LB, Ward RL, Wong JW.

Genes Chromosomes Cancer. 2015 May;54(5):303-14. doi: 10.1002/gcc.22243. Epub 2015 Feb 27.

PMID:
25726927
24.

Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation.

Kothari N, Kim R, Jorissen RN, Desai J, Tie J, Wong HL, Faragher I, Jones I, Day FL, Li S, Sakthinandeswaren A, Palmieri M, Lipton L, Schell M, Teer JK, Shibata D, Yeatman T, Sieber OM, Gibbs P, Tran B.

Acta Oncol. 2015 Apr;54(4):487-92. doi: 10.3109/0284186X.2014.990158. Epub 2014 Dec 31. Erratum in: Acta Oncol. 2017 Feb;56(2):375.

25.

Mutational analysis of genes coding for cell surface proteins in colorectal cancer cell lines reveal novel altered pathways, druggable mutations and mutated epitopes for targeted therapy.

Donnard E, Asprino PF, Correa BR, Bettoni F, Koyama FC, Navarro FC, Perez RO, Mariadason J, Sieber OM, Strausberg RL, Simpson AJ, Jardim DL, Reis LF, Parmigiani RB, Galante PA, Camargo AA.

Oncotarget. 2014 Oct 15;5(19):9199-213.

26.

The intestinal epithelial cell differentiation marker intestinal alkaline phosphatase (ALPi) is selectively induced by histone deacetylase inhibitors (HDACi) in colon cancer cells in a Kruppel-like factor 5 (KLF5)-dependent manner.

Shin J, Carr A, Corner GA, Tögel L, Dávalos-Salas M, Tran H, Chueh AC, Al-Obaidi S, Chionh F, Ahmed N, Buchanan DD, Young JP, Malo MS, Hodin RA, Arango D, Sieber OM, Augenlicht LH, Dhillon AS, Weber TK, Mariadason JM.

J Biol Chem. 2014 Sep 5;289(36):25306-16. doi: 10.1074/jbc.M114.557546. Epub 2014 Jul 18. Erratum in: J Biol Chem. 2015 Jun 19;290(25):15392. Dávaos-Salas, Mercedes [Corrected to Dávalos-Salas, Mercedes].

27.

Functional screening identifies miRNAs influencing apoptosis and proliferation in colorectal cancer.

Christensen LL, Holm A, Rantala J, Kallioniemi O, Rasmussen MH, Ostenfeld MS, Dagnaes-Hansen F, Øster B, Schepeler T, Tobiasen H, Thorsen K, Sieber OM, Gibbs P, Lamy P, Hansen TF, Jakobsen A, Riising EM, Helin K, Lubinski J, Hagemann-Madsen R, Laurberg S, Ørntoft TF, Andersen CL.

PLoS One. 2014 Jun 3;9(6):e96767. doi: 10.1371/journal.pone.0096767. eCollection 2014.

28.

Epigenetic inactivation of the candidate tumor suppressor USP44 is a frequent and early event in colorectal neoplasia.

Sloane MA, Wong JW, Perera D, Nunez AC, Pimanda JE, Hawkins NJ, Sieber OM, Bourke MJ, Hesson LB, Ward RL.

Epigenetics. 2014 Aug;9(8):1092-100. doi: 10.4161/epi.29222. Epub 2014 May 16.

29.

Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.

Mouradov D, Sloggett C, Jorissen RN, Love CG, Li S, Burgess AW, Arango D, Strausberg RL, Buchanan D, Wormald S, O'Connor L, Wilding JL, Bicknell D, Tomlinson IP, Bodmer WF, Mariadason JM, Sieber OM.

Cancer Res. 2014 Jun 15;74(12):3238-47. doi: 10.1158/0008-5472.CAN-14-0013. Epub 2014 Apr 22.

30.

Widespread FRA1-dependent control of mesenchymal transdifferentiation programs in colorectal cancer cells.

Diesch J, Sanij E, Gilan O, Love C, Tran H, Fleming NI, Ellul J, Amalia M, Haviv I, Pearson RB, Tulchinsky E, Mariadason JM, Sieber OM, Hannan RD, Dhillon AS.

PLoS One. 2014 Mar 21;9(3):e88950. doi: 10.1371/journal.pone.0088950. eCollection 2014.

31.

Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution.

Dewhurst SM, McGranahan N, Burrell RA, Rowan AJ, Grönroos E, Endesfelder D, Joshi T, Mouradov D, Gibbs P, Ward RL, Hawkins NJ, Szallasi Z, Sieber OM, Swanton C.

Cancer Discov. 2014 Feb;4(2):175-185. doi: 10.1158/2159-8290.CD-13-0285. Epub 2014 Jan 19.

32.

Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations.

Mouradov D, Domingo E, Gibbs P, Jorissen RN, Li S, Soo PY, Lipton L, Desai J, Danielsen HE, Oukrif D, Novelli M, Yau C, Holmes CC, Jones IT, McLaughlin S, Molloy P, Hawkins NJ, Ward R, Midgely R, Kerr D, Tomlinson IP, Sieber OM.

Am J Gastroenterol. 2013 Nov;108(11):1785-93. doi: 10.1038/ajg.2013.292. Epub 2013 Sep 17.

PMID:
24042191
33.

Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically.

Putoczki TL, Thiem S, Loving A, Busuttil RA, Wilson NJ, Ziegler PK, Nguyen PM, Preaudet A, Farid R, Edwards KM, Boglev Y, Luwor RB, Jarnicki A, Horst D, Boussioutas A, Heath JK, Sieber OM, Pleines I, Kile BT, Nash A, Greten FR, McKenzie BS, Ernst M.

Cancer Cell. 2013 Aug 12;24(2):257-71. doi: 10.1016/j.ccr.2013.06.017.

34.

PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer.

Day FL, Jorissen RN, Lipton L, Mouradov D, Sakthianandeswaren A, Christie M, Li S, Tsui C, Tie J, Desai J, Xu ZZ, Molloy P, Whitehall V, Leggett BA, Jones IT, McLaughlin S, Ward RL, Hawkins NJ, Ruszkiewicz AR, Moore J, Busam D, Zhao Q, Strausberg RL, Gibbs P, Sieber OM.

Clin Cancer Res. 2013 Jun 15;19(12):3285-96. doi: 10.1158/1078-0432.CCR-12-3614. Epub 2013 Apr 30.

35.

MiRNA-362-3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancer.

Christensen LL, Tobiasen H, Holm A, Schepeler T, Ostenfeld MS, Thorsen K, Rasmussen MH, Birkenkamp-Demtroeder K, Sieber OM, Gibbs P, Lubinski J, Lamy P; COLOFOL steering group, Laurberg S, Oster B, Hansen KQ, Hagemann-Madsen R, Byskov K, Ørntoft TF, Andersen CL.

Int J Cancer. 2013 Jul;133(1):67-78. doi: 10.1002/ijc.28010. Epub 2013 Feb 12.

36.

SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer.

Fleming NI, Jorissen RN, Mouradov D, Christie M, Sakthianandeswaren A, Palmieri M, Day F, Li S, Tsui C, Lipton L, Desai J, Jones IT, McLaughlin S, Ward RL, Hawkins NJ, Ruszkiewicz AR, Moore J, Zhu HJ, Mariadason JM, Burgess AW, Busam D, Zhao Q, Strausberg RL, Gibbs P, Sieber OM.

Cancer Res. 2013 Jan 15;73(2):725-35. doi: 10.1158/0008-5472.CAN-12-2706. Epub 2012 Nov 8.

37.

Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/β-catenin signalling thresholds for tumourigenesis.

Christie M, Jorissen RN, Mouradov D, Sakthianandeswaren A, Li S, Day F, Tsui C, Lipton L, Desai J, Jones IT, McLaughlin S, Ward RL, Hawkins NJ, Ruszkiewicz AR, Moore J, Burgess AW, Busam D, Zhao Q, Strausberg RL, Simpson AJ, Tomlinson IP, Gibbs P, Sieber OM.

Oncogene. 2013 Sep 26;32(39):4675-82. doi: 10.1038/onc.2012.486. Epub 2012 Oct 22.

38.

Investigation of the effects of DNA repair gene polymorphisms on the risk of colorectal cancer.

Tomlinson IP, Houlston RS, Montgomery GW, Sieber OM, Dunlop MG.

Mutagenesis. 2012 Mar;27(2):219-23. doi: 10.1093/mutage/ger070.

39.

New reagents for improved in vitro and in vivo examination of TGF-β signalling.

Luwor RB, Wang B, Nheu TV, Iaria J, Tsantikos E, Hibbs ML, Sieber OM, Zhu HJ.

Growth Factors. 2011 Oct;29(5):211-8. doi: 10.3109/08977194.2011.615311.

PMID:
21913800
40.

PHLDA1 expression marks the putative epithelial stem cells and contributes to intestinal tumorigenesis.

Sakthianandeswaren A, Christie M, D'Andreti C, Tsui C, Jorissen RN, Li S, Fleming NI, Gibbs P, Lipton L, Malaterre J, Ramsay RG, Phesse TJ, Ernst M, Jeffery RE, Poulsom R, Leedham SJ, Segditsas S, Tomlinson IP, Bernhard OK, Simpson RJ, Walker F, Faux MC, Church N, Catimel B, Flanagan DJ, Vincan E, Sieber OM.

Cancer Res. 2011 May 15;71(10):3709-19. doi: 10.1158/0008-5472.CAN-10-2342. Epub 2011 May 10.

41.

KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.

Tie J, Lipton L, Desai J, Gibbs P, Jorissen RN, Christie M, Drummond KJ, Thomson BN, Usatoff V, Evans PM, Pick AW, Knight S, Carne PW, Berry R, Polglase A, McMurrick P, Zhao Q, Busam D, Strausberg RL, Domingo E, Tomlinson IP, Midgley R, Kerr D, Sieber OM.

Clin Cancer Res. 2011 Mar 1;17(5):1122-30. doi: 10.1158/1078-0432.CCR-10-1720. Epub 2011 Jan 14.

42.

Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.

Tie J, Gibbs P, Lipton L, Christie M, Jorissen RN, Burgess AW, Croxford M, Jones I, Langland R, Kosmider S, McKay D, Bollag G, Nolop K, Sieber OM, Desai J.

Int J Cancer. 2011 May 1;128(9):2075-84. doi: 10.1002/ijc.25555.

43.

Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer.

Jorissen RN, Gibbs P, Christie M, Prakash S, Lipton L, Desai J, Kerr D, Aaltonen LA, Arango D, Kruhøffer M, Orntoft TF, Andersen CL, Gruidl M, Kamath VP, Eschrich S, Yeatman TJ, Sieber OM.

Clin Cancer Res. 2009 Dec 15;15(24):7642-7651.

44.

DNA copy-number alterations underlie gene expression differences between microsatellite stable and unstable colorectal cancers.

Jorissen RN, Lipton L, Gibbs P, Chapman M, Desai J, Jones IT, Yeatman TJ, East P, Tomlinson IP, Verspaget HW, Aaltonen LA, Kruhøffer M, Orntoft TF, Andersen CL, Sieber OM.

Clin Cancer Res. 2008 Dec 15;14(24):8061-9. doi: 10.1158/1078-0432.CCR-08-1431.

45.

Promoter hypermethylation leads to decreased APC mRNA expression in familial polyposis and sporadic colorectal tumours, but does not substitute for truncating mutations.

Segditsas S, Sieber OM, Rowan A, Setien F, Neale K, Phillips RK, Ward R, Esteller M, Tomlinson IP.

Exp Mol Pathol. 2008 Dec;85(3):201-6. doi: 10.1016/j.yexmp.2008.09.006. Epub 2008 Oct 11.

PMID:
18977219
46.

APC and the three-hit hypothesis.

Segditsas S, Rowan AJ, Howarth K, Jones A, Leedham S, Wright NA, Gorman P, Chambers W, Domingo E, Roylance RR, Sawyer EJ, Sieber OM, Tomlinson IP.

Oncogene. 2009 Jan 8;28(1):146-55. doi: 10.1038/onc.2008.361. Epub 2008 Oct 6.

PMID:
18836487
47.

Analysis of copy number changes suggests chromosomal instability in a minority of large colorectal adenomas.

Jones AM, Thirlwell C, Howarth KM, Graham T, Chambers W, Segditsas S, Page KM, Phillips RK, Thomas HJ, Sieber OM, Sawyer EJ, Tomlinson IP.

J Pathol. 2007 Nov;213(3):249-56.

PMID:
17893889
48.

Investigation of pathogenic mechanisms in multiple colorectal adenoma patients without germline APC or MYH/MUTYH mutations.

Thirlwell C, Howarth KM, Segditsas S, Guerra G, Thomas HJ, Phillips RK, Talbot IC, Gorman M, Novelli MR, Sieber OM, Tomlinson IP.

Br J Cancer. 2007 Jun 4;96(11):1729-34. Epub 2007 May 15.

49.

Disease severity and genetic pathways in attenuated familial adenomatous polyposis vary greatly but depend on the site of the germline mutation.

Sieber OM, Segditsas S, Knudsen AL, Zhang J, Luz J, Rowan AJ, Spain SL, Thirlwell C, Howarth KM, Jaeger EE, Robinson J, Volikos E, Silver A, Kelly G, Aretz S, Frayling I, Hutter P, Dunlop M, Guenther T, Neale K, Phillips R, Heinimann K, Tomlinson IP.

Gut. 2006 Oct;55(10):1440-8. Epub 2006 Feb 4.

50.

Tissue, cell and stage specificity of (epi)mutations in cancers.

Sieber OM, Tomlinson SR, Tomlinson IP.

Nat Rev Cancer. 2005 Aug;5(8):649-55. Review.

PMID:
16056260

Supplemental Content

Loading ...
Support Center